Childhood central nervous system germinoma

Summary

Childhood central nervous system germinoma (MONDO:0004452) is a disease and 6 clinical trials. Top therapeutic interventions include leucovorin and pazopanib hydrochloride. A subtype of central nervous system germinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood central nervous system germinoma
Mondo ID	MONDO:0004452
DOID	DOID:8078
NCIT	C27406
UMLS	C1332953
MedGen	272460
GARD	0024013
Is cancer (heuristic)	no

Also known as: Central nervous system germinoma · central nervous system germinoma of childhood · paediatric central nervous system germinoma · pediatric central nervous system germinoma

Disease family

This is a subtype of central nervous system germinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › central nervous system germinoma › childhood central nervous system germinoma

Related subtypes (2): brain germinoma, adult central nervous system germinoma

Subtypes (1): childhood brain germinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00281944	PHASE1	COMPLETED	Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
NCT00387920	PHASE1	COMPLETED	Sunitinib in Treating Young Patients With Refractory Solid Tumors
NCT00929903	PHASE1	COMPLETED	Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
NCT00994500	PHASE1	COMPLETED	Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
NCT01076530	PHASE1	COMPLETED	Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
NCT01088763	PHASE1	TERMINATED	Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEUCOVORIN	4	1
PAZOPANIB HYDROCHLORIDE	4	1
CHEMBL3109278	0	1